The recognition that a significant fraction of what historically has been classified as ovarian cancer is, in fact, a malignancy that arises in the fallopian tube mucosa comprises a paradigm shift in our understanding of these neoplasms. New etiologic and management opportunities have been created by this insight, both for women at increased genetic risk of ovarian cancer by virtue of being BRCA1/2 mutation carriers and, perhaps, for women in the general population as well. Cancer Prev Res; 8(5); 1–3. ©2015 AACR.
See related article by Daly et al., p. 342
- Received February 17, 2015.
- Accepted March 11, 2015.
- ©2015 American Association for Cancer Research.